Our contribution to the field of MDS! Multi-institutional efforts and great collaborations! Valeria Visconte Munich Leukemia Laboratory Simona Pagliuca Yihong Guan Hassan Awada Babal Jha MDS Foundation AA&MDSIF Tor Vergata Blood Advances

Defining remission following hematopoietic cell transplant for #myelofibrosis: an international expert panel consensus nature.com/articles/s4137… #MPNsm Leukemia Journal Nico Gagelmann DrDonalMcLornan MPN_Hub The EBMT The EBMT Trainee Committee

Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with #myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT nature.com/articles/s4140… #MPNsm #BMTsm EBMT The EBMT Trainee Committee DrDonalMcLornan Bone Marrow Transplantation

Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia | Nature Cancer nature.com/articles/s4301…

Privileged to share our recent research on #CMML at the National Taiwan University College of Medicine. #MDSsm #MPNsm

One of the conferences I’m most eager to be part of next year! #MPNsm ESH (Haematology) MPN_Hub

A key event bringing together researchers and clinicians interested in #MDSsm/#MPNsm! ESH (Haematology) International Consortium for MDS (icMDS) MDS Foundation AA&MDSIF MDS Hub MPN_Hub

link.springer.com/article/10.100… Splicing factor mutations in #CMML Nick Steinauer #SRSF2 #U2AF1 #ZRSR2 #SF3B1 Mayo Clinic Comprehensive Cancer Center Mayo Clinic Hematology-Oncology Fellowship

🧬 Among >17,000 NGS-screened patients, likely pathogenic #SH2B3 variants were enriched in suspected CMML (7.2%) and MPN (5.6%). When isolated, they were associated with ⬆️Hb and ⬆️platelets. nature.com/articles/s4140… #Hematology #Genomics #Myeloid

New publication 📝An exposure–response analysis, published in British Journal of Clinical Pharmacology (BJCP), shows fedratinib exposure is positively associated with SVR35 and TSS response in patients with #myelofibrosis. Learn more about fedratinib in MF: loom.ly/VlUa04w #MPN #MPNsm #MedNews #MedEd

It’s been 3 months, and I’ve settled in rather well to Taiwan’s clinical and research rhythm. Yet on different occasions, I still find myself wondering: how would Dan react, what would Tim say?

High JAK2V617F allele burden in low-risk PV: an additional recommendat... sciencedirect.com/science/articl… interesting paper and potential practice changer

👉👉👉Just out in Pubmed | Ph 1-2 results of #Tagraxofusp monotherapy in R/R Myelofibrosis MF | Blood Journals Portfolio #MPNSM led by Dr Abdulraheem Yacoub & Naveen Pemmaraju, MD Haris Ali Mrinal Patnaik Eunice Wang MD Vikas Gupta sciencedirect.com/science/articl…

Grateful and honoured to receive my 3rd (& final) ASH Abstract Achievement Award. My sincere thanks to my supervisors and colleagues for their guidance and support. Looking forward to sharing our work and thoughtful discussions at #ASH25. #MPNsm #MDSsm #CMML

Hemojuvelin as the center of attention for new targeted therapies for anemia and polycythemia vera #mpnsm American Journal of Hematology | Blood Research Journal | Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/aj…

What can we learn from multiple recently failed phase III clinical trials in higher-risk MDS? I hope you enjoy this new piece by Amer Zeidan MBBS,MHS ‏عامر زيدان and me in Blood Blood Journals Portfolio. ashpublications.org/blood/article-…

Decitabine-cedazuridine in p53 mutated MDS. Paper in Blood Advances. Here we took the results of Ascertain study and compared them with an MDACC mutated cohort. Oral dac may be the most active compound for this group of patients. The question is why? pubmed.ncbi.nlm.nih.gov/41170912/

Excited to share the results of the Global Phase III trial #SurpassET demonstrating superiority of ROPEG INFa2b for 2L for patients with essential thrombocythemia #ET Atrium Health Levine Cancer Wake Forest University School of Medicine sciencedirect.com/science/articl…

Excited to see long-term trial results using Danazol in #Telomere disorders in Blood Journals Portfolio Advances. Most relapsed after discontinuation but responded to re-initiation. No increased risk of clonal evolution. Nicholas Lee, MD Fernanda Gutierrez-Rodrigues Bhavisha Patel ashpublications.org/bloodadvances/…

Chronic myelomonocytic leukaemia in a nutshell! doi.org/10.1111/bjh.70… Mrinal Patnaik #CMML #MDSsm #MPNsm #BMTsm